GSK information hub: Initial maintenance therapy in COPD (contains brand information)
Content funded and provided by GSK
For healthcare professionals only
Prescribing information is available via a link at the bottom of the page
Expert perspectives on NICE recommendations for initial maintenance therapy in COPD
GSK funded and organised a roundtable meeting with respiratory experts to discuss the health-system impact of LAMA/LABA initial maintenance therapy in COPD. Attendees were paid an honorarium for their time by GSK. Watch the videos below to learn more. LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.
Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?
COPD: Have you done enough to implement guidelines?
Why you might want to review COPD patients receiving a LAMA
Expert perspectives on LAMA/LABA initial maintenance therapy in COPD and real life case studies
GSK interviewed respiratory experts Dr Daryl Freeman and Laura Rush to discuss the use of LAMA/LABAs as initial maintenance therapy for appropriate symptomatic COPD patients and real life COPD case studies. The speakers were paid an honorarium for their time by GSK. Watch the videos below to learn more. LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.
LAMA/LABA as initial maintenance therapy for appropriate symptomatic COPD patients
Since this video was recorded, another LAMA/LABA has been made available in the UK; there are currently 5 LAMA/LABAs
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
This link takes you to a third party website that is part of the Bristol-Myers Squibb Group and Pfizer Group. The Alliance (Bristol Myers Squibb Group and Pfizer Group) recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it. If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.